437 related articles for article (PubMed ID: 27636236)
61. Systematic review of vismodegib toxicity profile in the treatment of advanced basal cell carcinomas compared to other systemic therapies in dermatology.
Juhasz ML; Marmur ES
J Drugs Dermatol; 2014 Jun; 13(6):729-33. PubMed ID: 24918565
[TBL] [Abstract][Full Text] [Related]
62. Surgery after sonidegib treatment achieves complete response in locally advanced basal cell carcinoma of the face.
Paradisi A; Piccerillo A; Bocchino E; Cappilli S; Ricci C; Di Stefani A; Peris K
J Dermatol; 2024 Jan; 51(1):106-109. PubMed ID: 37732421
[TBL] [Abstract][Full Text] [Related]
63. Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months.
Dummer R; Lear JT; Guminski A; Leow LJ; Squittieri N; Migden M
J Am Acad Dermatol; 2021 Apr; 84(4):1162-1164. PubMed ID: 33358380
[No Abstract] [Full Text] [Related]
64. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.
Piérard-Franchimont C; Hermanns-Lê T; Paquet P; Herfs M; Delvenne P; Piérard GE
Future Oncol; 2015 Nov; 11(22):2997-3002. PubMed ID: 26437034
[TBL] [Abstract][Full Text] [Related]
65. Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study.
Moreno-Arrones OM; Béa-Ardebol S; Mayo-Martinez F; Pérez-Pastor G; Torres-Navarro I; Bonfill-Ortí M; Deza G; Ruiz-Salas V; Masferrer E; Feal C; Turrión-Merino L; Toll A; Yébenes M; Galiano-Mejías S; Jaka A; Ferrandiz-Pulido C; Florez A; Hernández-Hernández N; Fernández-de-Misa R; Rios-Buceta L; Sanmartin O
Actas Dermosifiliogr; 2023; 114(7):T565-T571. PubMed ID: 37302483
[TBL] [Abstract][Full Text] [Related]
66. Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study.
Moreno-Arrones OM; Béa-Ardebol S; Mayo-Martinez F; Pérez-Pastor G; Torres-Navarro I; Bonfill-Ortí M; Deza G; Ruiz-Salas V; Masferrer E; Feal C; Turrión-Merino L; Toll A; Yébenes M; Galiano-Mejías S; Jaka A; Ferrandiz-Pulido C; Florez A; Hernández-Hernández N; Fernández-de-Misa R; Rios-Buceta L; Sanmartin O
Actas Dermosifiliogr; 2023; 114(7):565-571. PubMed ID: 37088285
[TBL] [Abstract][Full Text] [Related]
67. Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review.
Patel S; Armbruster H; Pardo G; Archambeau B; Kim NH; Jeter J; Wu R; Kendra K; Contreras CM; Spaccarelli N; Dulmage B; Pootrakul L; Carr DR; Verschraegen C
PLoS One; 2024; 19(4):e0297531. PubMed ID: 38687774
[TBL] [Abstract][Full Text] [Related]
68. Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma.
Brinkhuizen T; Reinders MG; van Geel M; Hendriksen AJ; Paulussen AD; Winnepenninckx VJ; Keymeulen KB; Soetekouw PM; van Steensel MA; Mosterd K
J Am Acad Dermatol; 2014 Nov; 71(5):1005-8. PubMed ID: 25199678
[No Abstract] [Full Text] [Related]
69. Sonidegib efficacy and tolerability in advanced basal cell carcinoma: A single-center real-life experience.
Villani A; Fabbrocini G; Costa C; Scalvenzi M
J Am Acad Dermatol; 2022 Apr; 86(4):e175. PubMed ID: 34838876
[No Abstract] [Full Text] [Related]
70. Sonidegib (Odomzo) for basal cell carcinoma.
Med Lett Drugs Ther; 2016 Feb; 58(1489):31-2. PubMed ID: 26938701
[No Abstract] [Full Text] [Related]
71. Anal and rectal locally advanced basal cell carcinoma treated with sonidegib.
Conforti C; Toffoli L; Degrassi F; di Meo N; Zalaudek I
Dermatol Ther; 2022 Feb; 35(2):e15242. PubMed ID: 34854197
[No Abstract] [Full Text] [Related]
72. Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer.
Carpenter RL; Ray H
Drug Saf; 2019 Feb; 42(2):263-279. PubMed ID: 30649745
[TBL] [Abstract][Full Text] [Related]
73. Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.
Ali FR; Lear JT
Br J Dermatol; 2013 Jul; 169(1):53-7. PubMed ID: 23488543
[TBL] [Abstract][Full Text] [Related]
74. Vismodegib: a promising drug in the treatment of basal cell carcinomas.
Dirix L; Rutten A
Future Oncol; 2012 Aug; 8(8):915-28. PubMed ID: 22894666
[TBL] [Abstract][Full Text] [Related]
75. FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma.
Casey D; Demko S; Shord S; Zhao H; Chen H; He K; Putman A; Helms W; Keegan P; Pazdur R
Clin Cancer Res; 2017 May; 23(10):2377-2381. PubMed ID: 28073840
[TBL] [Abstract][Full Text] [Related]
76. Vismodegib: a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas.
Sobanko JF; Okman J; Miller C
J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s154-5. PubMed ID: 24085062
[TBL] [Abstract][Full Text] [Related]
77. Discovery and preclinical development of vismodegib.
Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
[TBL] [Abstract][Full Text] [Related]
78. Sonic Hedgehog pathway inhibitors: from clinical trials to clinical practice.
Yan BY; Hibler BP; Menge T; Dunn L; Ho AL; Rossi AM
Br J Dermatol; 2019 May; 180(5):1260-1261. PubMed ID: 30693471
[No Abstract] [Full Text] [Related]
79. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
Chang AL; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Orphanet J Rare Dis; 2016 Sep; 11(1):120. PubMed ID: 27581207
[TBL] [Abstract][Full Text] [Related]
80. Complete remission of an advanced basal cell carcinoma after only 3-month treatment with sonidegib: Report of a case and drug management during COVID-19 pandemic.
Villani A; Fabbrocini G; Costa C; Scalvenzi M
Dermatol Ther; 2020 Nov; 33(6):e14200. PubMed ID: 32870541
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]